Sevasemten News, Researches and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Latest Articles

MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy

Press Releases July 29, 2025 0

MetrioPharm announced today that the European Medicines Agency has...

Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy

Research July 29, 2025 1

Genethon has received approvals from regulatory authorities, MHRA and...

FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’

Press Releases July 29, 2025 0

Elevidys, a gene therapy for Duchenne Muscular Dystrophy (DMD)...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Treatments December 26, 2024 5

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Research January 5, 2025 6

The results of new gene therapy studies for Duchenne...

Duchenne Muscular Dystrophy: Treatment & Cost

Editorials January 2, 2025 1

The excitement you feel until your child is born...

Sevasemten

Must Read

Sarepta Reported Elevidys Gene Therapy for Duchenne Muscular Dystrophy will not be used in non-ambulatory patients

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

New Positive Functional Data From The RGX-202 Affinity Duchenne® Trial Phase 1/2 Reported By Regenxbio